96 results about "Genus Lactobacillus" patented technology

The invention discloses combined lactobacillus salivarius CCFM1327 capable of inhibiting foaming of macrophages and relieving periodontitis, and belongs to the technical field of microorganisms. According to the invention, the strain of combined lactobacillus salivarius CCFM1327 is obtained, and the combined lactobacillus salivarius has the effects of inhibiting foaming of macrophages and relieving periodontitis, which are specifically reflected in that the combined lactobacillus salivarius can inhibit foaming of RAW264.7 cells caused by ox-LDL; the growth of porphyromonas gingivalis can be effectively inhibited; the periodontal probing and diagnosing depth of the periodontitis rats can be obviously reduced; the number of pathogenic bacteria in the oral cavity of the periodontitis rat is reduced; the level of an inflammatory factor IL-17A in serum is reduced; alveolar bone loss of rats suffering from periodontitis is reduced; and the number of alveolar bone osteoclasts is reduced.

Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.

Provided is a composition for controlling uptake of microparticles into a body, the composition containing a lactic acid bacterium. The lactic acid bacterium is preferably any one selected from bacteria belonging to the genus Lactobacillus and bacteria belonging to the genus Streptococcus. For example, the lactic acid bacterium is a bacterium belonging to Lactobacillus delbrueckii, Lactobacillus paracasei, Lactobacillus gasseri, or Streptococcus thermophilus.

The invention belongs to the technical field of microorganisms, and particularly relates to an oligopeptide from lactobacillus plantarum extracellular vesicles and application of the oligopeptide. Specifically, the lactobacillus plantarum extracellular vesicles can recover the skin barrier; the expression of proinflammatory factors in a cell inflammation model can be reduced, and a relatively good anti-inflammatory effect is achieved. Metabolome analysis shows that effective substances having effects on skin barrier injury comprise oligopeptide KLQ; kLQ can regulate skin barrier related gene expression in the SDS-induced damaged cell model; and the expression of skin inflammation-related genes in the SDS-induced damaged cell model is regulated, so that the SDS-induced SDS-induced damaged cell model can be used as a medicine for treating skin barrier injury.

The present invention provides a composition comprising a white tea tree double fermentation product obtained by primary fermentation of a white tea tree extract using a microorganism of the genus Lactobacillus and secondary fermentation using a microorganism of the genus Bacillus. The composition has excellent effects of resisting oxidation, resisting inflammation, moisturizing skin, removing cutin, conditioning skin microorganisms and the like due to the inclusion of the white tea tree double fermentation product, and thus can be used as a raw material for cosmetics and the like.

The invention discloses an intestinal flora delivery system based on a lactobacillus biological membrane and a preparation method of the intestinal flora delivery system, the intestinal flora delivery system is based on the lactobacillus biological membrane, and the biological membrane particularly refers to a biological membrane system which is induced by lactobacillus spp. Through optimized culture conditions and is mature in structure. And after physical collection and mild homogenization treatment, a biological membrane fragment suspension mainly composed of an extracellular polymeric matrix is obtained. According to the invention, a treated lactobacillus biofilm matrix is used as a core carrier, and a compact natural three-dimensional network structure can provide an excellent physical barrier; meanwhile, the biological matrix has chemical buffering potential and good biocompatibility.

The invention provides lactobacillus gasseri JY01, and belongs to the technical field of probiotic application, the lactobacillus gasseri JY01 is preserved in Guangdong Microbial Culture Collection Center on May 21, 2025, the preservation number is GDMCC NO. 66341, and the nucleotide sequence is shown as SEQ ID No: 1. The strain is obtained by separating and purifying a pickle sample produced in Liaoning region of China, has multiple functions of producing gamma-aminobutyric acid (GABA) at high yield, reducing blood sugar, resisting oxidation, regulating gastrointestinal tracts and the like, and has very high application value and economic value.

The disclosure provides a composition configured for oral use, the composition including at least one filler and at least one oral care component, such as a probiotic, calcium glycerophosphate, urea, a quaternary ammonium salt, or a combination thereof. Example probiotics include probiotics from the genera selected from lactobacillus, streptococcus, and combinations thereof. The oral composition may additionally include one or more prebiotics selected from inulin, xylo-oligosaccharides (XOS), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), isomalto-oligosaccharide (IMO), and combinations thereof. The composition can take various forms, including the form of a gel, pastille, gum, chew, melt, tablet, lozenge, granular material, powder, or pouched product.

The present invention belongs to the field of food products, in particular fresh mozzarella, and provides packing water suitable for directly acidified fresh mozzarella comprising at least one lactic acid bacterium (LAB), preferably wherein the at least one LAB strain is selected from a Lactobacillus strain, a Lactiplantibacillus strain, a Lacticaseibacillus strain or a Lactococcus strain. The invention further provides LAB suitable for being comprised in the packing water of the present invention and methods for producing packaged fresh mozzarella using the packing water and LAB of the present invention.

The present invention relates to a method for treating conditions associated with weight loss in emaciation and cachexia with a probiotic composition and the use of a probiotic composition in the treatment of conditions associated with weight loss in emaciation and cachexia. The present invention provides a method of treating a condition associated with weight loss, the method comprising administering to a subject considered in need of such treatment a probiotic composition wherein the composition comprises at least two bacteria, each preferably selected from a different genus, the genus is preferably selected from the group consisting of Lactobacillus genus, Enterococcus genus and Bifidobacterium genus. The present invention also provides a probiotic composition for use in the treatment of a subject suffering from a condition associated with weight loss wherein the composition comprises at least two bacteria each preferably selected from a different genus, preferably selected from the group consisting of Lactobacillus genus, Enterococcus genus and Bifidobacterium genus.

The present invention relates to novel strains of Lactobacillus genus having extended shelf life properties, i.e., capable of extending the shelf life of food products (e.g., fermented milk products) at room temperature without severely impairing the antimicrobial, antifungal and / or anti-yeast effect ability of said strains when added to such products. According to another aspect, the present invention relates to an antimicrobial, antifungal or anti-yeast composition. According to yet another aspect, the present invention relates to a food product. According to another aspect, the present invention relates to a method for manufacturing a food product. According to another aspect, the present invention relates to the use of Lactobacillus strains for providing antifungal, antimicrobial and / or anti-yeast effects, for example in fermented milk products.

The invention discloses a lactobacillus brevis strain D15 for salt-reduced Pixian thick broad-bean sauce and application of the lactobacillus brevis strain D15. The preservation registration number of the strain D15 is CGMCC (China General Microbiological Culture Collection Center) No: 27698. The botanical classification of the strain D15 is short-growth-promoting lactobacillus in the bacterial field, the phylum of Thyrium, the Bacillus, the Lactobacillus, the Lactobacillus family and the Lactobacillus genus, and the Latin literature name of the strain D15 is Levibacillus brevis D15. The application of the strain D15 is as follows: firstly, the strain D15 is applied to preparation of salt-reduced Pixian thick broad-bean sauce; 2, application in preparation of salt-reduced chilli sauce; and 3, application in preparation of the salt-reduced broad bean sauce. After inoculation optimization is carried out on chili embryos or broad bean embryos by using the strain D15 disclosed by the invention, a salt-reduced fermentation system which takes chili and broad beans as raw materials and is under low salinity can be kept stable, the pH value is 4.2-4.5, and rancidity of the prepared fermented food is avoided; the enzyme activity can be obviously promoted, the fermentation time is shortened, the preparation cost is reduced, the flavor quality of the Pixian thick broad-bean sauce, the chili sauce and the broad bean sauce is obviously improved, and the industrial application value of the Pixian thick broad-bean sauce is obviously improved.

The present invention discloses a cosmetic composition and, more specifically, discloses a cosmetic composition capable of providing skin improving effects such as oxidation resistance, whitening, and wrinkle improvement by comprising a concentrated fermented product prepared by concentrating a mixed extract extracted from the root of kudzu vine and lentil seeds and fermenting the concentrated extract with a Lactobacillus strain.

The present invention provides an FPR2 agonist. Specifically, the FPR2 agonist comprises, as an active ingredient, outer membrane vesicles derived from at least one lactic acid bacterium selected from the group consisting of genus Lactobacillus, genus Lacticaseibacillus, genus Lactiplantibacillus, genus Ligilactobacillus, genus Lactococcus, and Streptococcus salivarius subsp. thermophilus.

The present invention provides a novel Lactobacillus sp. strain, which has high antibacterial activity against various pathogenic bacteria, including bacteria associated with fish diseases and dental cavities, inhibits the production of melanin and promotes the synthesis of collagen, and thus can be utilized as a material for a variety of foods and medicines, and the use thereof.

The present invention addresses the problem of providing a composition, for activating plasmacytoid dendritic cells, which has a high level of safety and can be taken by a large number of people more easily. A composition for activating plasmacytoid dendritic cells according to the present invention contains one or more lactic acid bacteria selected from Lactobacillus lactic acid bacteria (excluding Lactobacillus helveticus), Lacticaseibacillus lactic acid bacteria, and lactic acid bacteria belonging to Streptococcus thermophilus. It is to be noted that the above-mentioned composition for activating plasmacytoid dendritic cells preferably contains Lactobacillus lactic acid bacteria (excluding Lactobacillus helveticus), Lacticaseibacillus lactic acid bacteria, and lactic acid bacteria belonging to Streptococcus thermophilus.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

The present invention addresses the problem of providing a more easily and highly safe preventive or inhibitory measure against an increase in periodontal disease pathogenic bacteria. The fermented milk according to the present invention contains lactic acid bacteria belonging to the genus Lactobacillus and has a function of increasing IgA crossing pathogenic bacteria of periodontal diseases in human saliva. It is required to be illustrated that the lactic acid bacteria of the genus Lactobacillus are preferably lactic acid bacteria of the genus Lactobacillus capable of producing exopolysaccharides, more preferably Lactobacillus delbrueckii, further preferably Lactobacillus delbrueckii subsp. Bulgaricus, and particularly preferably Lactobacillus delbrueckii subsp. Bulgaricus OLL1073R-1 (accession number: FERM BP-10741) lactic acid bacteria.

The present disclosure relates to a probiotic composition that delivers a mixture or blend of 7 probiotic strains including Lactobacillus spp. (L. plantarum, L. acidophilus, and L. rhamnosus) and Bifidobacterium spp. (B. lactis, B. infantis, B. breve, and B. longum). The probiotic compositions of the disclosure comprise these 7 strains that may either be a live organism capable of proliferation in the subject, a non-living strain such as, but not limited to, a heat-killed proliferative strain, or a combination thereof. In addition to the Lactobacillus and Bifidobacterium strains, the compositions can include micronutrients such as Vitamin D, zinc, lactoferrin, HMOs, DHA+ARA, and inulin, in various combinations to support infant health.

This invention relates to the fields of microbial genetic engineering and brewing technology, and provides a PDC1 gene mutant strain resistant to 2-phenylethanol and its application in the brewing of wheat-aroma baijiu. The mutant strain is *Saccharomyces cerevisiae* PDC1_473 (HM 03), with the preservation number CCTCC M20252996. The PDC1 gene of this strain has a base mutation from T to C at position 473. When this mutant strain is applied to the solid-state fermentation of wheat-aroma baijiu, it becomes the absolutely dominant fungal community, significantly altering the microbial community structure of the fermentation system, inhibiting the growth of various conditionally pathogenic and spoilage bacteria, strengthening the fermentation environment centered on *Lactobacillus*, and significantly enhancing the rose, citrus, grassy, ​​fatty, and caramel aromas of the baijiu. It imparts a pleasant, rich ester aroma and complex aroma to the baijiu, increasing its fullness, and has broad application potential in the brewing of wheat-aroma baijiu.

The invention provides polygonatum kingianum hepta-oligosaccharide and application thereof.Fermented polygonatum kingianum is prepared through fermentation of pediococcus ethanolidurans, fermented polygonatum kingianum polysaccharide is extracted from the fermented polygonatum kingianum, and the brand-new polygonatum kingianum hepta-oligosaccharide is obtained through extraction and purification, and the structural formula of the polygonatum kingianum hepta-oligosaccharide is alpha-D-Glcp-1-(2-beta-D-Fruf-1) 5-2-beta-D-Fruf. The probiotic can be selectively utilized by intestinal microbiota at cecum and colon parts, the relative abundance of beneficial intestinal microbiota is specifically increased, the proliferation of enterococcus and lactobacillus is remarkably promoted, the pH value of colon can be reduced, the intestinal microecological balance is optimized, the biosynthesis of short-chain fatty acid is stimulated, and the probiotic has an excellent prebiotic effect and a wide application prospect.

The present invention is related to at least one isolated bacterial strain selected from at least one of the species selected from the group comprising or, alternatively, consisting of: i) Lactobacillus plantarum, ii) Lactobacillus acidophilus, and iii) Lactobacillus crispatus, or mixtures of said at least one isolated bacterial strain thereof, for use in a method of metals gut microbial bioremediation. Preferably, said metals involved in the gut microbial bioremediation are heavy metals, which are selected from the group comprising or, alternatively, consisting of Ag, Be, Ba, Cd, Cr, Mn, Hg, Pb, Cu, V, and As preferably from Cd, Cr, Hg, and Pb; or Al, or mixtures thereof. In particular, said at least one isolated bacterial strain belonging to the specie i) Lactobacillus plantarum is selected from the group comprising or, alternatively, consisting of Lactiplantibacillus plantarum 476LL 20 bi LP01 (LMG P- 21021), Lactiplantibacillus plantarum 776 / 1 bi LP02 (LMG P-21020), and Lactiplantibacillus plantarum LP14 (DSM 33401) or mixtures thereof, said at least one isolated bacterial strain belonging to the specie ii) Lactobacillus acidophilus is selected from the group comprising or, alternatively, consisting of Lactobacillus acidophilus LA02 (DSM 21717), and Lactobacillus acidophilus LA06 (DSM 23033), and said at least one isolated bacterial strain belonging to the specie iii) Lactobacillus crispatus is identified as Lactobacillus crispatus LCR04 (DSM 33487). Furthermore, the present invention regards a mixture comprising at least one isolated bacterial strain as above indicated, as well as a composition comprising said mixture, for use in a method of metals gut microbial bioremediation, wherein said metals involved in the gut microbial bioremediation are heavy metals, which are selected from the group comprising or, alternatively, consisting of Ag, Be, Ba, Cd, Cr, Mn, Hg, Pb, Cu, V, and As preferably from Cd, Cr, Hg, and Pb; or Al, or mixtures thereof and in the prevention and or reduction of the harmful effects of heavy metals on gut health.

The present invention relates to novel strains of Lactobacillus genus having extended shelf life properties, i.e., capable of extending the shelf life of food products (e.g., fermented milk products) at room temperature without severely impairing the antimicrobial, antifungal and / or anti-yeast effect ability of said strains when added to such products. The invention also relates to methods of producing such novel strains, in particular to methods of producing such novel strains via adaptive evolution.

The present invention relates to orally administered postbiotic compositions, and discloses orally administered postbiotic compositions used for the treatment of solid tumors in patients, particularly colon cancer and / or lung cancer. The compositions comprise lysates of probiotic microorganisms belonging to the genera Bacillus, Bifidobacterium, Lactobacillus, Saccharomyces, and Streptococcus.

The present application discloses an oral metastatic composition for use in the treatment of solid tumors in a patient, in particular colon and / or lung cancer, comprising lysates of probiotic microorganisms derived from the genus Bacillus, Bifidobacterium, Lactobacillus, Saccharomyces and Streptococcus.

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.

The present invention provides histamine H1 receptor antagonism-based uses for various uses (histamine H1 receptor antagonism uses, uses to improve sleep quality and / or modulate balance of the autonomic nervous system, and uses to improve sleep quality and / or modulate balance of the autonomic nervous system. And a use for preventing the onset of autonomic nervous system dysfunction or a symptom caused thereby or for improving autonomic nervous system dysfunction or a symptom caused thereby). The present invention relates to: a composition comprising, as an active ingredient, at least one substance selected from the group consisting of indole-3-lactic acid, alpha-Asp-Phe, Val-Arg, Asp-Gly-Glu, and salts thereof, or a lactic acid bacteria culture supernatant (not containing lactic acid bacteria cells) of a lactic acid bacteria belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus, and the genus Lactobacillus; the liquid supernatant contains at least one substance selected from the group consisting of indole-3-lactic acid, alpha-Asp-Phe, Val-Arg, Asp-Gly-Glu, and salts thereof. The liquid supernatant contains at least one substance selected from the group consisting of indole-3-lactic acid, alpha-Asp-Phe, Val-Arg, Asp-Gly-Glu.

The present invention relates to a multi-postbiotics-compounded rejuvenating essence, which includes the following components in percentage by weight: 8.0-13.0% of butanediol, 2.0-3.0% of triglyceride octoate / caprate / succinate, 2.0-3.0% of polyglutamate sodium, 0.5-1.0% of extract of Japanese Ardisia herb stems, 0.5-1.0% of yeast / rice ferment filtrate, 0.5-1.0% of fission yeast mycelium ferment filtrate, 0.5-1.0% of lactobacillus / mung bean extract / sodium glutamate ferment filtrate, 0.5-1.0% of lactobacillus ferment, 0.5-1.0% of bacillus / rice bran extract / soybean extract ferment filtrate, 0.5-1.0% of Streptococcus thermophilus ferment, 0.1-0.2% of collargol, and 65.3-79.4% of deionized water, wherein the essence is put in an airtight container and is injected with hydrogen. The present invention can achieve an effect of repairing the skin, and the combination of active substances with the hydrogen injected has a prominent effect on reducing the amount of allergic erythema and alleviating the recurrent allergic redness and rashes.

Provided are a technique capable of reducing harmful bacteria without reducing beneficial bacteria, as well as a flora improver and an antibacterial agent using the same. According to the present invention, the number of harmful bacteria can be suppressed without suppressing the number of beneficial bacteria. Therefore, according to the present invention, the flora can be effectively improved. In addition, since the antibacterial agent of the present invention does not reduce beneficial bacteria, it is expected to reduce side effects such as diarrhea caused by the decrease in beneficial bacteria. 【Solution means】 A flora improver characterized by using agarooligosaccharide as an active ingredient and using the active ingredient in any of the following usage amounts (a) to (c); (a) A usage amount that does not suppress the number of bacteria belonging to the genus Bifidobacterium, (b) A usage amount that does not suppress the number of bacteria belonging to the genus Lactobacillus, (c) A usage amount of 80 mg or more and less than 12,000 mg per day.

The present invention pertains to a method for producing an antimicrobial composition preferably comprising piceol. Moreover, the invention relates to an antimicrobial composition comprising or consisting of piceol, preferably in an excess amount compared to picein, further plant-derived substances and optionally picein. The invention further relates to a cosmetic, personal care, household, home care, pet care or pharmaceutical product comprising said antimicrobial composition. Moreover, the invention relates to the use of a microorganism, preferably a lactobacillus species, for producing an antimicrobial composition comprising piceol from a composition, preferably a plant-extract, comprising picein. In addition, the invention relates to the use of shikimic acid for increasing the antimicrobial efficacy of piceol and / or to the use of piceol for increasing the antimicrobial efficacy of shikimic acid. Further embodiments and aspects of the invention are presented in the attached claims as well as in the description and examples below.